Salestools LogoSalestools
Salestools LogoSalestools
Biotech

Synthego

Synthego raises $200M Series C at $1.2B valuation

$200M
Total Raised
Series C
Latest Round
2012
Founded
200+
Employees
3565 Haven Avenue, Redwood City, CA 94063
1 min read

Quick Facts

Valuation
$1.2B
Latest Round Size
$200M
Latest Round Date
June 2024

Synthego: Series C Funding Round

Synthego has successfully raised $200M in Series C funding, reaching a valuation of $1.2B.

Company Overview

CRISPR genome engineering tools

Funding Details

The Series C round was led by Founders Fund, with participation from 8VC, Menlo Ventures, Paladin Capital Group, Tencent.

Company Information

  • Headquarters: 3565 Haven Avenue, Redwood City, CA 94063
  • Founded: 2012
  • Employees: 200+
  • Category: Biotech

Investment

Synthego plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Founders Fund: Verified investor in Series C
  • 8VC: Verified investor in Series C
  • Menlo Ventures: Verified investor in Series C
  • Paladin Capital Group: Verified investor in Series C
  • Tencent: Verified investor in Series C

Key Investors

Founders Fund
Lead Investor
Verified investor in Series C
8VC
Investor
Verified investor in Series C
Menlo Ventures
Investor
Verified investor in Series C
Paladin Capital Group
Investor
Verified investor in Series C
Tencent
Investor
Verified investor in Series C

Topics

verified(3080)real-funding(3080)series-c(264)biotech(108)synthego(1)3565-haven-avenue(1)

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Torl Biotherapeutics

Torl Biotherapeutics raises $96M Series C at $500M valuation

Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...

Editorial Team
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics

Nilo Therapeutics raises $101M Series A at $450M valuation

Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...

Editorial Team
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics

Arthrosi Therapeutics raises $153M Series E at $800M valuation

Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...

Editorial Team
Editorial Team
Oct 8, 2025
1 min read•$153M